Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data

British Medical Journal

Volumn 331, Issue 7520, 2005, Pages 810-814

  Webster, Angela C ^a   Woodroffe, Rebecca C ^d   Taylor, Rod S ^d   Chapman, Jeremy R ^b   Craig, Jonathan C ^c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ALOPECIA; ARTICLE; CHOLESTASIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; GINGIVA HYPERPLASIA; HEADACHE; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SYSTEMATIC REVIEW; TREMOR; VOMITING;

CYCLOSPORINE; FORECASTING; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 26644469263     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38569.471007.AE     Document Type: Article

References (14)

1. Chadban S. Transplantation: ANZDATA registry report 2003. Adelaide: Australian and New Zealand Dialysis And Transplant Registry, 2003:65.
2. Immunosuppression: 2004 annual report of the U.S. Organ Procurement and Transplantation Network and the scientific registry of transplant recipients: transplant data 1994-2003. Ann Arbor, MI: HHS/HRSA/OSP/DOT and UNOS, 2004.
3. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000;20:108-25.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83.
5. Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000;20:176-87.
6. Cosio FG, Larson TS. Cardiovascular disease after transplantation: do we know all of the variables? Am J Transplant 2003;3:915-6.
7. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999;353:1083-91.
8. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
9. Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant outcome. Am J Transplant 2003;3:933-41.
10. Lachenbruch PA, Rosenberg AS, Bonvini E, Cavaill A. Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am J Transplant 2004;4:451-7.
11. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73.
12. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104-7.
13. Heisel OH. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-95.
14. National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in adults. London: NICE, 2004. (Technology appraisal 85.)